Prenetics Global Past Earnings Performance
Past criteria checks 0/6
Prenetics Global's earnings have been declining at an average annual rate of -6.7%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 29.5% per year.
Key information
-6.7%
Earnings growth rate
18.8%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | -29.5% |
| Return on equity | -23.3% |
| Net Margin | -187.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Prenetics Global Limited's (NASDAQ:PRE) Earnings Haven't Escaped The Attention Of Investors
Oct 12
Prenetics Global Limited (NASDAQ:PRE) Looks Just Right With A 29% Price Jump
May 29Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues
Apr 08Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%
Jan 07Prenetics Global GAAP EPS of -$2.91, revenue of $51.72M
Sep 09Revenue & Expenses Breakdown
How Prenetics Global makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 23 | -43 | 42 | 12 |
| 31 Mar 24 | 23 | -50 | 46 | 11 |
| 31 Dec 23 | 22 | -54 | 50 | 12 |
| 30 Sep 23 | 280 | -18 | 184 | 21 |
| 30 Jun 23 | 279 | -23 | 98 | 18 |
| 31 Mar 23 | 201 | -168 | 184 | 15 |
| 31 Dec 22 | 13 | -226 | 154 | 6 |
| 30 Sep 22 | 288 | -278 | 231 | 17 |
| 30 Jun 22 | 283 | -343 | 234 | 16 |
| 31 Mar 22 | 310 | -209 | 129 | 13 |
| 31 Dec 21 | 13 | -219 | 54 | 6 |
| 30 Sep 21 | 238 | -94 | 67 | 6 |
| 30 Jun 21 | 190 | -4 | 43 | 5 |
| 31 Mar 21 | 119 | 1 | 29 | 4 |
| 31 Dec 20 | 65 | -2 | 23 | 3 |
| 31 Dec 19 | 9 | -20 | 18 | 3 |
Quality Earnings: PRE is currently unprofitable.
Growing Profit Margin: PRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRE is unprofitable, and losses have increased over the past 5 years at a rate of 6.7% per year.
Accelerating Growth: Unable to compare PRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRE is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).
Return on Equity
High ROE: PRE has a negative Return on Equity (-23.33%), as it is currently unprofitable.